EMEA (Europe, Middle East and Africa) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Report 2017

December 2017 | 116 pages | ID: ED5591E968EEN
QYResearch

Abstracts

In this report, the EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Units), revenue (Million USD), market share and growth rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications for these regions, from 2012 to 2022 (forecast)

• Europe: Germany, France, UK, Russia, Italy and Benelux;
• Middle East: Saudi Arabia, Israel, UAE and Iran;
• Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications market competition by top manufacturers/players, with Commercializing Biomarkers in Therapeutic and Diagnostic Applications sales volume (K Units), price (USD/Unit), revenue (Million USD) and market share for each manufacturer/player; the top players including

• Roche
• Dako (Agilent Technologies)
• Merck
• BD
• Abbott
• Genesys Biolabs(20/20GeneSystems)
• Affymetrix
• Agendia
• ALMAC
• Arrayit
• Biocartic
• BG Medicine
• Thermo Fisher
• BGI

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into

• Consumables
• Services
• Software

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including

• Oncology
• Cardiology
• Neurology
• Other

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

EMEA (Europe, Middle East and Africa) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Report 2017

1 COMMERCIALIZING BIOMARKERS IN THERAPEUTIC AND DIAGNOSTIC APPLICATIONS OVERVIEW

1.1 Product Overview and Scope of Commercializing Biomarkers in Therapeutic and Diagnostic Applications
1.2 Classification of Commercializing Biomarkers in Therapeutic and Diagnostic Applications
  1.2.1 EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size (Sales) Comparison by Type (2012-2022)
  1.2.2 EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size (Sales) Market Share by Type (Product Category) in 2016
  1.2.3 Consumables
  1.2.4 Services
  1.2.5 Software
1.3 EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market by Application/End Users
  1.3.1 EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (Volume) and Market Share Comparison by Application (2012-2022
  1.3.2 Oncology
  1.3.3 Cardiology
  1.3.4 Neurology
  1.3.5 Other
1.4 EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market by Region
  1.4.1 EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 Europe Status and Prospect (2012-2022)
  1.4.3 Middle East Status and Prospect (2012-2022)
  1.4.4 Africa Status and Prospect (2012-2022)
1.5 EMEA Market Size (Value and Volume) of Commercializing Biomarkers in Therapeutic and Diagnostic Applications (2012-2022)
  1.5.1 EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2012-2022)
  1.5.2 EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Growth Rate (2012-2022)

2 EMEA COMMERCIALIZING BIOMARKERS IN THERAPEUTIC AND DIAGNOSTIC APPLICATIONS COMPETITION BY MANUFACTURERS/PLAYERS/SUPPLIERS, REGION, TYPE AND APPLICATION

2.1 EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Competition by Players/Manufacturers
  2.1.1 EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Volume and Market Share of Major Players (2012-2017)
  2.1.2 EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Share by Players (2012-2017)
  2.1.3 EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sale Price by Players (2012-2017)
2.2 EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications (Volume and Value) by Type/Product Category
  2.2.1 EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Market Share by Type (2012-2017)
  2.2.2 EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Market Share by Type (2012-2017)
  2.2.3 EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sale Price by Type (2012-2017)
2.3 EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications (Volume) by Application
2.4 EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications (Volume and Value) by Region
  2.4.1 EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Market Share by Region (2012-2017)
  2.4.2 EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Market Share by Region (2012-2017)
  2.4.3 EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Price by Region (2012-2017)

3 EUROPE COMMERCIALIZING BIOMARKERS IN THERAPEUTIC AND DIAGNOSTIC APPLICATIONS (VOLUME, VALUE AND SALES PRICE), BY PLAYERS, COUNTRIES, TYPE AND APPLICATION

3.1 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Value (2012-2017)
  3.1.1 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Volume and Growth Rate (2012-2017)
  3.1.2 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Growth Rate (2012-2017)
3.2 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Market Share by Type
3.3 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Market Share by Application
3.4 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Volume and Value (Revenue) by Countries
  3.4.1 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Volume by Countries (2012-2017)
  3.4.2 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Countries (2012-2017)
  3.4.3 Germany Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2012-2017)
  3.4.4 France Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2012-2017)
  3.4.5 UK Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2012-2017)
  3.4.6 Russia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2012-2017)
  3.4.7 Italy Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2012-2017)
  3.4.8 Benelux Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2012-2017)

4 MIDDLE EAST COMMERCIALIZING BIOMARKERS IN THERAPEUTIC AND DIAGNOSTIC APPLICATIONS (VOLUME, VALUE AND SALES PRICE), BY REGION, TYPE AND APPLICATION

4.1 Middle East Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Value (2012-2017)
  4.1.1 Middle East Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Volume and Growth Rate (2012-2017)
  4.1.2 Middle East Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Growth Rate (2012-2017)
4.2 Middle East Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Market Share by Type
4.3 Middle East Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Market Share by Application
4.4 Middle East Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Volume and Value (Revenue) by Countries
  4.4.1 Middle East Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Volume by Countries (2012-2017)
  4.4.2 Middle East Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Countries (2012-2017)
  4.4.3 Saudi Arabia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2012-2017)
  4.4.4 Israel Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2012-2017)
  4.4.5 UAE Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2012-2017)
  4.4.6 Iran Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2012-2017)

5 AFRICA COMMERCIALIZING BIOMARKERS IN THERAPEUTIC AND DIAGNOSTIC APPLICATIONS (VOLUME, VALUE AND SALES PRICE) BY PLAYERS, COUNTRIES, TYPE AND APPLICATION

5.1 Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Value (2012-2017)
  5.1.1 Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Volume and Growth Rate (2012-2017)
  5.1.2 Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Growth Rate (2012-2017)
5.2 Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Market Share by Type
5.3 Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Market Share by Application
5.4 Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Volume and Value (Revenue) by Countries
  5.4.1 Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Volume by Countries (2012-2017)
  5.4.2 Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Countries (2012-2017)
  5.4.3 South Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2012-2017)
  5.4.4 Nigeria Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2012-2017)
  5.4.5 Egypt Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2012-2017)
  5.4.6 Algeria Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2012-2017)

6 EMEA COMMERCIALIZING BIOMARKERS IN THERAPEUTIC AND DIAGNOSTIC APPLICATIONS MANUFACTURERS/PLAYERS PROFILES AND SALES DATA

6.1 Roche
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Type, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 Dako (Agilent Technologies)
  6.2.1 Company Basic Information, Manufacturing Base and Competitors
  6.2.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Type, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 Dako (Agilent Technologies) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 Merck
  6.3.1 Company Basic Information, Manufacturing Base and Competitors
  6.3.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Type, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 BD
  6.4.1 Company Basic Information, Manufacturing Base and Competitors
  6.4.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Type, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 BD Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 Abbott
  6.5.1 Company Basic Information, Manufacturing Base and Competitors
  6.5.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Type, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Abbott Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview
6.6 Genesys Biolabs(20/20GeneSystems)
  6.6.1 Company Basic Information, Manufacturing Base and Competitors
  6.6.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Type, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 Genesys Biolabs(20/20GeneSystems) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Main Business/Business Overview
6.7 Affymetrix
  6.7.1 Company Basic Information, Manufacturing Base and Competitors
  6.7.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Type, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 Affymetrix Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin (2012-2017)
  6.7.4 Main Business/Business Overview
6.8 Agendia
  6.8.1 Company Basic Information, Manufacturing Base and Competitors
  6.8.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Type, Application and Specification
    6.8.2.1 Product A
    6.8.2.2 Product B
  6.8.3 Agendia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin (2012-2017)
  6.8.4 Main Business/Business Overview
6.9 ALMAC
  6.9.1 Company Basic Information, Manufacturing Base and Competitors
  6.9.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Type, Application and Specification
    6.9.2.1 Product A
    6.9.2.2 Product B
  6.9.3 ALMAC Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin (2012-2017)
  6.9.4 Main Business/Business Overview
6.10 Arrayit
  6.10.1 Company Basic Information, Manufacturing Base and Competitors
  6.10.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Type, Application and Specification
    6.10.2.1 Product A
    6.10.2.2 Product B
  6.10.3 Arrayit Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin (2012-2017)
  6.10.4 Main Business/Business Overview
6.11 Biocartic
6.12 BG Medicine
6.13 Thermo Fisher
6.14 BGI

7 COMMERCIALIZING BIOMARKERS IN THERAPEUTIC AND DIAGNOSTIC APPLICATIONS MANUFACTURING COST ANALYSIS

7.1 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Commercializing Biomarkers in Therapeutic and Diagnostic Applications Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 EMEA COMMERCIALIZING BIOMARKERS IN THERAPEUTIC AND DIAGNOSTIC APPLICATIONS MARKET FORECAST (2017-2022)

11.1 EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue and Price Forecast (2017-2022)
  11.1.1 EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate Forecast (2017-2022)
  11.1.2 EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Growth Rate Forecast (2017-2022)
  11.1.3 EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Price and Trend Forecast (2017-2022)
11.2 EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.3 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.4 Middle Eastt Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.5 Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.6 EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Forecast by Type (2017-2022)
11.7 EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Forecast by Application (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer


The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of Commercializing Biomarkers in Therapeutic and Diagnostic Applications
Figure EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Volume (K Units) by Type (2012-2022)
Figure EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Volume Market Share by Type (Product Category) in 2016
Figure Consumables Product Picture
Figure Services Product Picture
Figure Software Product Picture
Figure EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Volume (K Units) by Application (2012-2022)
Figure EMEA Sales Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Application in 2016
Figure Oncology Examples
Table Key Downstream Customer in Oncology
Figure Cardiology Examples
Table Key Downstream Customer in Cardiology
Figure Neurology Examples
Table Key Downstream Customer in Neurology
Figure Other Examples
Table Key Downstream Customer in Other
Figure EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size (Million USD) by Region (2012-2022)
Figure Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (Million USD) and Growth Rate (2012-2022)
Figure Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (Million USD) Status and Forecast by Countries
Figure Middle East Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (Million USD) and Growth Rate (2012-2022)
Figure Middle East Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (Million USD) Status and Forecast by Countries
Figure Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (Million USD) and Growth Rate (2012-2022)
Figure Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (Million USD) Status and Forecast by Countries
Figure EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Volume and Growth Rate (2012-2022)
Figure EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (Million USD) and Growth Rate (2012-2022)
Figure EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Major Players Product Sales Volume (K Units) (2012-2017)
Table EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Volume (K Units) of Major Players (2012-2017)
Table EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Share by Players (2012-2017)
Figure 2016 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Share by Players
Figure 2017 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Share by Players
Figure EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Major Players Product Revenue (Million USD) (2012-2017)
Table EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (Million USD) by Players (2012-2017)
Table EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Share by Players (2012-2017)
Table 2016 EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Share by Players
Table 2017 EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Share by Players
Table EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sale Price (USD/Unit) by Players (2012-2017)
Table EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units) and Market Share by Type (2012-2017)
Table EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Share by Type (2012-2017)
Figure Sales Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Type (2012-2017)
Figure EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Market Share by Type (2012-2017)
Table EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (Million USD) and Market Share by Type (2012-2017)
Table EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Type in 2016
Table EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sale Price (USD/Unit) by Type (2012-2017)
Table EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units) and Market Share by Application (2012-2017)
Table EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Share by Application (2012-2017)
Figure Sales Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Application (2012-2017)
Figure EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Market Share by Application in 2016
Table EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units) and Market Share by Region (2012-2017)
Table EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Share by Region (2012-2017)
Figure Sales Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Region (2012-2017)
Figure EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Market Share in 2016
Table EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (Million USD) and Market Share by Region (2012-2017)
Table EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Share by Region (2012-2017)
Figure Revenue Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Region (2012-2017)
Figure EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share Regions in 2016
Table EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Price (USD/Unit) by Region (2012-2017)
Figure Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units) and Growth Rate (2012-2017)
Figure Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Growth Rate (2012-2017)
Table Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units) by Type (2012-2017)
Table Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Type (2012-2017)
Figure Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Type in 2016
Table Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units) by Application (2012-2017)
Table Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Application (2012-2017)
Figure Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Application in 2016
Table Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units) by Countries (2012-2017)
Table Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Market Share by Countries (2012-2017)
Figure Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Market Share by Countries (2012-2017)
Figure Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Market Share by Countries in 2016
Table Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (Million USD) by Countries (2012-2017)
Table Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share by Countries (2012-2017)
Figure Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share by Countries (2012-2017)
Figure Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share by Countries in 2016
Figure Germany Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units) and Growth Rate (2012-2017)
Figure France Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units) and Growth Rate (2012-2017)
Figure UK Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units) and Growth Rate (2012-2017)
Figure Russia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units) and Growth Rate (2012-2017)
Figure Italy Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units) and Growth Rate (2012-2017)
Figure Benelux Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units) and Growth Rate (2012-2017)
Figure Middle East Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units) and Growth Rate (2012-2017)
Figure Middle East Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (Million USD) and Growth Rate (2012-2017)
Table Middle East Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units) by Type (2012-2017)
Table Middle East Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Type (2012-2017)
Figure Middle East Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Type (2012-2017)
Table Middle East Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units) by Applications (2012-2017)
Table Middle East Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Applications (2012-2017)
Figure Middle East Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Market Share by Application in 2016
Table Middle East Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Volume (K Units) by Countries (2012-2017)
Table Middle East Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Volume Market Share by Countries (2012-2017)
Figure Middle East Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Volume Market Share by Countries in 2016
Table Middle East Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (Million USD) by Countries (2012-2017)
Table Middle East Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share by Countries (2012-2017)
Figure Middle East Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share by Countries (2012-2017)
Figure Middle East Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share by Countries in 2016
Figure Saudi Arabia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units) and Growth Rate (2012-2017)
Figure Israel Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units) and Growth Rate (2012-2017)
Figure UAE Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units) and Growth Rate (2012-2017)
Figure Iran Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units) and Growth Rate (2012-2017)
Figure Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units) and Growth Rate (2012-2017)
Figure Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (Million USD) and Growth Rate (2012-2017)
Table Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units) by Type (2012-2017)
Table Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Market Share by Type (2012-2017)
Figure Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Market Share by Type (2012-2017)
Figure Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Market Share by Type in 2016
Table Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units) by Application (2012-2017)
Table Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Market Share by Application (2012-2017)
Figure Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Market Share by Application (2012-2017)
Table Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Volume (K Units) by Countries (2012-2017)
Table Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Market Share by Countries (2012-2017)
Figure Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Market Share by Countries (2012-2017)
Figure Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Market Share by Countries in 2016
Table Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (Million USD) by Countries (2012-2017)
Table Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share by Countries (2012-2017)
Figure Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share by Countries (2012-2017)
Figure Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share by Countries in 2016
Figure South Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units) and Growth Rate (2012-2017)
Figure Nigeria Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units) and Growth Rate (2012-2017)
Figure Egypt Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units) and Growth Rate (2012-2017)
Figure Algeria Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units) and Growth Rate (2012-2017)
Table Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications Basic Information List
Table Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units) and Growth Rate (2012-2017)
Figure Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Market Share in EMEA (2012-2017)
Figure Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share in EMEA (2012-2017)
Table Dako (Agilent Technologies) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Basic Information List
Table Dako (Agilent Technologies) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Dako (Agilent Technologies) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units) and Growth Rate (2012-2017)
Figure Dako (Agilent Technologies) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Market Share in EMEA (2012-2017)
Figure Dako (Agilent Technologies) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share in EMEA (2012-2017)
Table Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications Basic Information List
Table Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units) and Growth Rate (2012-2017)
Figure Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Market Share in EMEA (2012-2017)
Figure Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share in EMEA (2012-2017)
Table BD Commercializing Biomarkers in Therapeutic and Diagnostic Applications Basic Information List
Table BD Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure BD Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units) and Growth Rate (2012-2017)
Figure BD Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Market Share in EMEA (2012-2017)
Figure BD Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share in EMEA (2012-2017)
Table Abbott Commercializing Biomarkers in Therapeutic and Diagnostic Applications Basic Information List
Table Abbott Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Abbott Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units) and Growth Rate (2012-2017)
Figure Abbott Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Market Share in EMEA (2012-2017)
Figure Abbott Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share in EMEA (2012-2017)
Table Genesys Biolabs(20/20GeneSystems) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Basic Information List
Table Genesys Biolabs(20/20GeneSystems) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Genesys Biolabs(20/20GeneSystems) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units) and Growth Rate (2012-2017)
Figure Genesys Biolabs(20/20GeneSystems) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Market Share in EMEA (2012-2017)
Figure Genesys Biolabs(20/20GeneSystems) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share in EMEA (2012-2017)
Table Affymetrix Commercializing Biomarkers in Therapeutic and Diagnostic Applications Basic Information List
Table Affymetrix Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Affymetrix Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units) and Growth Rate (2012-2017)
Figure Affymetrix Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Market Share in EMEA (2012-2017)
Figure Affymetrix Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share in EMEA (2012-2017)
Table Agendia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Basic Information List
Table Agendia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Agendia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units) and Growth Rate (2012-2017)
Figure Agendia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Market Share in EMEA (2012-2017)
Figure Agendia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share in EMEA (2012-2017)
Table ALMAC Commercializing Biomarkers in Therapeutic and Diagnostic Applications Basic Information List
Table ALMAC Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure ALMAC Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units) and Growth Rate (2012-2017)
Figure ALMAC Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Market Share in EMEA (2012-2017)
Figure ALMAC Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share in EMEA (2012-2017)
Table Arrayit Commercializing Biomarkers in Therapeutic and Diagnostic Applications Basic Information List
Table Arrayit Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Arrayit Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units) and Growth Rate (2012-2017)
Figure Arrayit Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Market Share in EMEA (2012-2017)
Figure Arrayit Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share in EMEA (2012-2017)
Table Biocartic Commercializing Biomarkers in Therapeutic and Diagnostic Applications Basic Information List
Table BG Medicine Commercializing Biomarkers in Therapeutic and Diagnostic Applications Basic Information List
Table Thermo Fisher Commercializing Biomarkers in Therapeutic and Diagnostic Applications Basic Information List
Table BGI Commercializing Biomarkers in Therapeutic and Diagnostic Applications Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Commercializing Biomarkers in Therapeutic and Diagnostic Applications
Figure Manufacturing Process Analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications
Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Industrial Chain Analysis
Table Raw Materials Sources of Commercializing Biomarkers in Therapeutic and Diagnostic Applications Major Manufacturers in 2016
Table Major Buyers of Commercializing Biomarkers in Therapeutic and Diagnostic Applications
Table Distributors/Traders List
Figure EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units) and Growth Rate Forecast (2017-2022)
Figure EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Growth Rate Forecast (2017-2022)
Figure EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Price (USD/Unit) and Trend Forecast (2017-2022)
Table EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units) Forecast by Region (2017-2022)
Figure EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Market Share Forecast by Region (2017-2022)
Table EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (Million USD) Forecast by Region (2017-2022)
Figure EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share Forecast by Region (2017-2022)
Table Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units) Forecast by Countries (2017-2022)
Figure Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Market Share Forecast by Countries (2017-2022)
Table Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share Forecast by Countries (2017-2022)
Table Middle East Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units) Forecast by Countries (2017-2022)
Figure Middle East Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Market Share Forecast by Countries (2017-2022)
Table Middle East Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Middle East Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share Forecast by Countries (2017-2022)
Table Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units) Forecast by Countries (2017-2022)
Figure Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Market Share Forecast by Countries (2017-2022)
Table Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share Forecast by Countries (2017-2022)
Table EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units) Forecast by Type (2017-2022)
Figure EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Market Share Forecast by Type (2017-2022)
Table EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units) Forecast by Application (2017-2022)
Figure EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Market Share Forecast by Application (2017-2022)
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources